Venøse tromboliske hændelser af grad 3 – 5 sås hos op mod 7, 8% af patienter behandlet med kemoterapi plus bevacizumab i forhold til op mod 4, 9% hos patienter, som fik kemoterapi alene.
Grade 3-5 venous thromboembolic events have been reported in up to 7.8% of patients treated with chemotherapy plus bevacizumab compared with up to 4.9% in patients treated with chemotherapy alone.